AT-312

AT-312 is a small molecule investigational drug that acts as a selective agonist for the nociceptin opioid peptide receptor. It has been studied primarily for its potential role in modulating pain and drug addiction behaviors through this mechanism. In preclinical studies, AT-312 demonstrated the ability to decrease the rewarding effects of morphine and cocaine, suggesting possible utility as a therapeutic agent for substance use disorders. The compound was originally developed in academic collaboration; commercial developers are not clearly identified in available literature. AT-312 is not a marketed pharmaceutical, and there is no evidence of clinical trials or regulatory filings for use in humans.